ISB News

ISB on Cover of C&En Magazine

By ISBUSA

ISB researcher Sarah Li was featured on the cover of C&EN Magazine on Nov. 18. The cover story is about how instrumentation companies are teaming up with research organizations to gain access to valuable work that could help refine or develop new technologies. ISB's Dr. Robert Moritz comments about our collaboration with AB Sciex for the story.

Excerpt from the piece:

"Building on this work, AB Sciex formed a partnership with the Institute for Systems Biology, a Seattle-based nonprofit headed by Leroy Hood. In February, ISB and AB Sciex signed a three-year agreement to collaborate on developing MS methods and technology in proteomics, applying SWATH to build biomarker libraries.

ISB scientists have known people at AB Sciex for many years, says Robert L. Moritz, ISB’s research director for proteomics. “We have had very much aligned thoughts about advancing proteomics. The latest partnership was more formalized because it was much larger.” ISB uses AB Sciex instruments, and the two sides exchange people and expertise."

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.